Ann: SUDA Licenses a Novel iNKT Cell Therapy Platform, page-10

One thing is for sure, Hopper wants to cash in on CAR-T, going now 3 different ways to fine tune regular CAR-T by increasing efficacy and reducing toxicity to break the solid tumor barrier.

But as at CHM and IMU, still years to get it to the market and probably a lot of CR'S to come. Unless, IMU gets taken over and Team IMU restarts with the next generation of their IP and $$$$$$$$$$$$$$$ at SUD or CHM.

But first, let's see what the CR price will be and what the Sophies will do with the shares and probably truckloads of free oppies.

GLTA